Either the adjuvanted influenza vaccine, Fluad Quad (NIP-funded) or the high dose influenza vaccine, Fluzone High Dose Quadrivalent is recommended in preference to standard-dose egg-based or cell-based influenza vaccine for adults aged ≥65 years. See also Vaccine information.
Influenza-associated mortality rates are highest among adults aged ≥65 years.4 Vaccinating elderly people reduces hospitalisations from influenza and pneumonia, and all-cause mortality.8